Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities
Craig A. Elmets, Craig L. Leonardi, Dawn Marie R. Davis, et al.
Journal of the American Academy of Dermatology (2019) Vol. 80, Iss. 4, pp. 1073-1113
Closed Access | Times Cited: 377

Showing 1-25 of 377 citing articles:

Pathophysiology, Clinical Presentation, and Treatment of Psoriasis
April W. Armstrong, Charlotte Read
JAMA (2020) Vol. 323, Iss. 19, pp. 1945-1945
Closed Access | Times Cited: 1509
Psoriasis Prevalence in Adults in the United States
April W. Armstrong, Manan D. Mehta, Clayton W. Schupp, et al.
JAMA Dermatology (2021) Vol. 157, Iss. 8, pp. 940-940
Open Access | Times Cited: 328
2024 ESC Guidelines for the management of elevated blood pressure and hypertension
John W. McEvoy, Cian P. McCarthy, Rosa María Bruno, et al.
European Heart Journal (2024)
Closed Access | Times Cited: 267
Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients
Alan Menter, Kelly M. Cordoro, Dawn Marie R. Davis, et al.
Journal of the American Academy of Dermatology (2019) Vol. 82, Iss. 1, pp. 161-201
Closed Access | Times Cited: 172
Treatment guidelines in psoriatic arthritis
Alexis Ogdie, Laura C. Coates, Dafna D. Gladman
Lara D. Veeken (2019) Vol. 59, Iss. Supplement_1, pp. i37-i46
Open Access | Times Cited: 152
Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis
Andrew Blauvelt, Craig L. Leonardi, Melinda Gooderham, et al.
JAMA Dermatology (2020) Vol. 156, Iss. 6, pp. 649-649
Open Access | Times Cited: 151
Use of IL-23 Inhibitors for the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive Review
Kevin Yang, Allen S. W. Oak, Boni E. Elewski
American Journal of Clinical Dermatology (2020) Vol. 22, Iss. 2, pp. 173-192
Open Access | Times Cited: 143
EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 2: specific clinical and comorbid situations
Alexander Nast, Catherine Smith, Phyllis I. Spuls, et al.
Journal of the European Academy of Dermatology and Venereology (2021) Vol. 35, Iss. 2, pp. 281-317
Open Access | Times Cited: 142
Cardiovascular Risk in Patients With Psoriasis
Michael Garshick, Nicole L. Ward, James G. Krueger, et al.
Journal of the American College of Cardiology (2021) Vol. 77, Iss. 13, pp. 1670-1680
Open Access | Times Cited: 122
Signaling pathways and targeted therapies for psoriasis
Jia Guo, H. Zhang, Wenrui Lin, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 116
Psoriasis and metabolic syndrome: implications for the management and treatment of psoriasis
Jashin J. Wu, Arthur Kavanaugh, Mark Lebwohl, et al.
Journal of the European Academy of Dermatology and Venereology (2022) Vol. 36, Iss. 6, pp. 797-806
Open Access | Times Cited: 106
Association of Lipid-Lowering Drugs With Risk of Psoriasis
Sizheng Steven Zhao, Z.Z.N. Yiu, Anne Barton, et al.
JAMA Dermatology (2023) Vol. 159, Iss. 3, pp. 275-275
Open Access | Times Cited: 47
Association between systemic immune inflammation index, systemic inflammation response index and adult psoriasis: evidence from NHANES
Rui Ma, Lian Cui, Jiangluyi Cai, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 30
The global, regional, and national burden of psoriasis in 195 countries and territories, 1990 to 2017: A systematic analysis from the Global Burden of Disease Study 2017
Sino Mehrmal, Prabhdeep Uppal, Natalie Nedley, et al.
Journal of the American Academy of Dermatology (2020) Vol. 84, Iss. 1, pp. 46-52
Open Access | Times Cited: 99
The TNF/IL‐23/IL‐17 axis—Head‐to‐head trials comparing different biologics in psoriasis treatment
Lisa Lynn ten Bergen, Aleksandra Petrovič, Anders Krogh Aarebrot, et al.
Scandinavian Journal of Immunology (2020) Vol. 92, Iss. 4
Open Access | Times Cited: 95
A Phase IV, Randomized, Double-Blind, Placebo-Controlled Crossover Study of the Effects of Ustekinumab on Vascular Inflammation in Psoriasis (the VIP-U Trial)
Joel M. Gelfand, Daniel B. Shin, Abass Alavi, et al.
Journal of Investigative Dermatology (2019) Vol. 140, Iss. 1, pp. 85-93.e2
Open Access | Times Cited: 94
A Randomized Placebo-Controlled Trial of Secukinumab on Aortic Vascular Inflammation in Moderate-to-Severe Plaque Psoriasis (VIP-S)
Joel M. Gelfand, Daniel B. Shin, Kristina Callis Duffin, et al.
Journal of Investigative Dermatology (2020) Vol. 140, Iss. 9, pp. 1784-1793.e2
Open Access | Times Cited: 74
Interleukin-17 and Interleukin-23: A Narrative Review of Mechanisms of Action in Psoriasis and Associated Comorbidities
Alan Menter, Gerald G. Krueger, So Yeon Paek, et al.
Dermatology and Therapy (2021) Vol. 11, Iss. 2, pp. 385-400
Open Access | Times Cited: 60
Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data
Alice B. Gottlieb, Atul Deodhar, Iain B. McInnes, et al.
Acta Dermato Venereologica (2022) Vol. 102, pp. adv00698-adv00698
Open Access | Times Cited: 53
Lipid Alterations and Metabolism Disturbances in Selected Inflammatory Skin Diseases
Julia Nowowiejska, Anna Baran, Iwona Flisiak
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 8, pp. 7053-7053
Open Access | Times Cited: 27
Real‐life effectiveness and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: A 104‐week multicenter retrospective study – IL PSO (ITALIAN LANDSCAPE PSORIASIS)
Luigi Gargiulo, Luciano Ibba, Piergiorgio Malagoli, et al.
Journal of the European Academy of Dermatology and Venereology (2023) Vol. 37, Iss. 5, pp. 1017-1027
Open Access | Times Cited: 25
The Impact of Diet and Physical Activity on Psoriasis: A Narrative Review of the Current Evidence
Ewa Duchnik, Joanna Kruk, Aleksandra Tuchowska, et al.
Nutrients (2023) Vol. 15, Iss. 4, pp. 840-840
Open Access | Times Cited: 25
Efficacy and safety of oral roflumilast for moderate-to-severe psoriasis—a randomized controlled trial (PSORRO)
Mette Gyldenløve, Howraman Meteran, Jennifer Astrup Sørensen, et al.
The Lancet Regional Health - Europe (2023) Vol. 30, pp. 100639-100639
Open Access | Times Cited: 24
Cardiovascular comorbidity in psoriasis – psoriatic inflammation is more than just skin deep
Katharina S. Kommoss, Alexander Enk, Mathias Heikenwälder, et al.
JDDG Journal der Deutschen Dermatologischen Gesellschaft (2023) Vol. 21, Iss. 7, pp. 718-725
Open Access | Times Cited: 22
Emerging Oral Therapies for the Treatment of Psoriasis: A Review of Pipeline Agents
Anastasia Drakos, Tiago Torres, Ronald Vender
Pharmaceutics (2024) Vol. 16, Iss. 1, pp. 111-111
Open Access | Times Cited: 10
Page 1 - Next Page

Scroll to top